MURRAY MEDS SIGNS SUPPLY AGREEMENT WITH AUSTRALIAN CANNABINOID COMPANY

• Murray Meds to supply medicinal cannabis dried flower, concentrate and final dose oils to Australian cannabinoid company
• The customer distributes premium medicinal cannabinoid products and services
• ECS shareholders approved the acquisition of 100% of Murray Meds on 2 March, 2021 with settlement to occur in the near term

ECS Botanics Holdings Ltd (ASX: ECS or Company) is pleased to announce Murray Meds has entered into a three-year non-exclusive agreement to supply medicinal cannabis dried flower and medicinal cannabis concentrate to Cronos Australia — Operations Pty Ltd (CA), an Australian cannabinoid company.

The non-exclusive agreement follows Murray Meds’ three-year supply agreement with London-based pharmaceuticals distribution company The Armour Group for the sale and export of medicinal cannabis oils in the UK and Germany, as announced earlier this year (see announcement dated 15 February 2021).

The latest agreement with CA is for the supply of:

• THC dried cannabis flower in jars
• Bulk dried cannabis flower
• THC API
• Medicinal cannabis oil in 30 & 50 ml bottles

The minimum spend across the life of the non-exclusive agreement is $750,000, with a potential spend of approximately $470,000 in the first year, subject to the Company satisfying certain revised sale price obligations.

The agreement can be terminated as follows:

• Immediately in the event that the Company fails to satisfy the revised sale price obligation.
• Upon ten (10) business days notice if the Company or CA breaches any provision of the agreement and fails or is unable to cure such breach within thirty (30) days.
• Immediately in the event that the Company fails to establish and maintain industry quality standards required under Applicable Law at its site.
• Immediately in the event that CA fails to make any payment when due and has not remedied such non-payment within ten (10) business days following receipt of written notice.
• Immediately in the event that the Company and or CA is subject to an insolvency event.
• Immediately in the event that a Governmental Authority were to restrict any material part of CA’s or the Company’s business.

Under and in accordance with the terms of the agreement, the specific commercial terms around pricing and units remain confidential.

ECS Botanics Managing Director Alex Keach commented:

“This is the second supply contract Murray Meds has signed in recent weeks and validates that a low capex and operating medicinal cannabis facility can still meet pharmaceutical quality of the oil and premium priced dry flower market. I am so pleased that this narrative is becoming a reality in the market place.

“ECS has previously collaborated and worked closely with the customer. We look forward to furthering this relationship and, with the acquisition of Murray Meds, expanding the ECS sales network from our production hubs in Victoria and Tasmania.”

Murray Meds has a fully licensed medicinal cannabis cultivation and manufacturing facility which holds a Cultivation, Research and Manufacturing Licence from the Australian Office of Drug Control and permits to cultivate and produce 3,500 kilograms of medicinal cannabis. Murray Meds also holds a TGA Good Manufacturing Practice manufacture licence for dried flower, oils and tinctures.

For further information, please contact:

Alexander Keach
Managing Director
alex@ecsbotanics.com.au
+61 419 323 059

Jason Hine
Chief Operations Officer
jason@ecsbotanics.com.au
+61 419 922 259

Authorised on behalf of ECS by Alex Keach, Managing Director